Reply to thread

The BI contract runs through 2028.

Our pipeline has the Alzheimer’s drug that will most likely get approved & an obesity indication for tirzepitide …both by the end of next year.


Not even counting the specialty drugs that will be launched over the next 2 years, so there are lots of opportunities and job security at Lilly.


PC3 actually has the easy job at the moment. Just maintain JR & EM. So keep offices in samples & remind them of formulary coverage and their job is done. Easiest time in pharma is just maintaining a drug after it’s been established